Phase I dose escalation and pharmacokinetic study on the nanoparticle formulation of polymeric micellar paclitaxel for injection in patients with advanced solid malignancies
Conclusions PM-paclitaxel showed high MTD without additional toxicity, and exhibited desirable antitumor activity. The recommended dose of PM paclitaxel for phase II study is 300 mg/m2.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Investigational New Drugs | Nanotechnology | Study | Toxicology